Analysis of kinetic curve and model-based perfusion parameters on dynamic contrast enhanced MRI in breast cancer patients: Correlations with dominant stroma type

被引:20
作者
Yim, Hyunee [1 ]
Kang, Doo Kyoung [2 ]
Jung, Yong Sik [3 ]
Jeon, Gyeong Sik [4 ]
Kim, Tae Hee [2 ]
机构
[1] Ajou Univ, Sch Med, Dept Pathol, Suwon 443380, Gyeonggi Do, South Korea
[2] Ajou Univ, Sch Med, Dept Radiol, Suwon 443380, Gyeonggi Do, South Korea
[3] Ajou Univ, Sch Med, Dept Surg, Suwon 443380, Gyeonggi Do, South Korea
[4] CHA Univ, CHA Bundang Med Ctr, Dept Radiol, Coll Med, Pocheon Si, South Korea
关键词
Breast cancer; Stroma; Magnetic resonance imaging; Perfusion; Kinetic curve; TUMOR-INFILTRATING LYMPHOCYTES; INVASIVE DUCTAL CARCINOMA; PROGNOSTIC-FACTORS; IN-SITU; GROWTH; RATIO; FIBROBLASTS; CELLS; ANGIOGENESIS; CHEMOTHERAPY;
D O I
10.1016/j.mri.2015.07.010
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: Our purpose was to evaluate imaging findings of breast cancers according to the dominant stroma type by using kinetic curve analysis and model-based perfusion parameters from dynamic contrast-enhanced magnetic resonance imaging. Methods: From March 2011 to September 2011, 64 cancers in 64 patients were included for data analysis. Kinetic curve analysis and model based perfusion parameters (Ktrans, Kep and ye) were obtained using dynamic contrast-enhanced magnetic resonance imaging and post-processing software. Imaging characteristics were analyzed according to the tumor-stroma ratio and dominant stroma type. Results: ye values were significantly lower in tumors with more than 50% cellularity (0.44 vs. 0.29, p = 0.008). Histologic grade, estrogen receptor status and subtype of cancer (triple negative versus non-triple negative) were significantly different (p = 0.009, p = 0.019 and p = 0.03, respectively). Median Kep values were different between collagen dominant, fibroblast dominant and lymphocyte dominant groups. By post hoc comparisons, mean Kep values were significantly higher in lymphocyte dominant group than collagen dominant group (p = 0.003). Ktrans and Ve values were not significantly different according to dominant stroma type (p = 0.351 and p = 0.257, respectively). In multivariate regression analysis, nuclear grade (p = 0.021) and dominant stroma type (collagen dominant, p = 0.017) were independently correlated with Kep values. In terms of the dominant stroma type, the collagen dominant type showed a decrease of 0.247 in Kep values, compared with the fibroblast-dominant type (p = 0.017). Conclusions: Ve values were significantly lower in tumors with high tumor-stroma ratio. Kep values were significantly lower in breast cancers with dominant collagen type and higher in cancers with high nuclear grade. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:60 / 65
页数:6
相关论文
共 39 条
  • [1] The prognostic significance of tumor-associated stroma in invasive breast carcinoma
    Ahn, Soomin
    Cho, Junhun
    Sung, Jiyoun
    Lee, Jeong Eon
    Nam, Seok Jin
    Kim, Kyoung-Mee
    Cho, Eun Yoon
    [J]. TUMOR BIOLOGY, 2012, 33 (05) : 1573 - 1580
  • [2] Breast Tissue Composition and Susceptibility to Breast Cancer
    Boyd, Norman F.
    Martin, Lisa J.
    Bronskill, Michael
    Yaffe, Martin J.
    Duric, Neb
    Minkin, Salomon
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (16): : 1224 - 1237
  • [3] Inflammation and cancer
    Coussens, LM
    Werb, Z
    [J]. NATURE, 2002, 420 (6917) : 860 - 867
  • [4] Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients
    de Kruijf, Esther M.
    van Nes, Johanna G. H.
    de Velde, Cornelis J. H. van
    Putter, Hein
    Smit, Vincent T. H. B. M.
    Liefers, Gerrit Jan
    Kuppen, Peter J. K.
    Tollenaar, Rob A. E. M.
    Mesker, Wilma E.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2011, 125 (03) : 687 - 696
  • [5] Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854)
    Dekker, T. J. A.
    van de Velde, C. J. H.
    van Pelt, G. W.
    Kroep, J. R.
    Julien, J-P.
    Smit, V. T. H. B. M.
    Tollenaar, R. A. E. M.
    Mesker, W. E.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (02) : 371 - 379
  • [6] Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers
    Denkert, Carsten
    von Minckwitz, Gunter
    Brase, Jan C.
    Sinn, Bruno V.
    Gade, Stephan
    Kronenwett, Ralf
    Pfitzner, Berit M.
    Salat, Christoph
    Loi, Sherene
    Schmitt, Wolfgang D.
    Schem, Christian
    Fisch, Karin
    Darb-Esfahani, Silvia
    Mehta, Keyur
    Sotiriou, Christos
    Wienert, Stephan
    Klare, Peter
    Andre, Fabrice
    Klauschen, Frederick
    Blohmer, Jens-Uwe
    Krappmann, Kristin
    Schmidt, Marcus
    Tesch, Hans
    Kuemmel, Sherko
    Sinn, Peter
    Jackisch, Christian
    Dietel, Manfred
    Reimer, Toralf
    Untch, Michael
    Loibl, Sibylle
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) : 983 - 991
  • [7] The accuracy of pharmacokinetic parameter measurement in DCE-MRI of the breast at 3 T
    Di Giovanni, P.
    Azlan, C. A.
    Ahearn, T. S.
    Semple, S. I.
    Gilbert, F. J.
    Redpath, T. W.
    [J]. PHYSICS IN MEDICINE AND BIOLOGY, 2010, 55 (01) : 121 - 132
  • [8] 3-T Dynamic Contrast-Enhanced MRI of the Breast: Pharmacokinetic Parameters Versus Conventional Kinetic Curve Analysis
    El Khouli, Riham H.
    Macura, Katarzyna J.
    Kamel, Ihab R.
    Jacobs, Michael A.
    Bluemke, David A.
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2011, 197 (06) : 1498 - 1505
  • [9] The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
    Gooden, M. J. M.
    de Bock, G. H.
    Leffers, N.
    Daemen, T.
    Nijman, H. W.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 105 (01) : 93 - 103
  • [10] Griffiths L, 1997, CANCER RES, V57, P570